Abstract
CD47 is an important innate immune checkpoint through its interaction with its inhibitory receptor on macrophages, signal-regulatory protein α (SIRPα). Therapeutic blockade of CD47–SIRPα interactions is a promising immuno-oncology treatment that promotes clearance of cancer cells. However, CD47–SIRPα interactions also maintain homeostatic lymphocyte levels. In this study, we report that the mouse splenic marginal zone B cell population is dependent on intact CD47–SIRPα interactions and blockade of CD47 leads to the loss of these cells. This depletion is accompanied by elevated levels of monocyte-recruiting chemokines CCL2 and CCL7 and infiltration of CCR2+Ly6Chi monocytes into the mouse spleen. In the absence of CCR2 signaling, there is no infiltration and reduced marginal zone B cell depletion. These data suggest that CD47 blockade leads to clearance of splenic marginal zone B cells. Key Points CD47 blockade leads to rapid but resolvable splenic marginal zone B cell depletion. Anti-CD47 mAb induced CCL2/CCL7 is accompanied by CCR2+ monocyte splenic infiltration.
Funding Information
  • Virginia and D.K. Ludwig Fund for Cancer Research (NA)
  • Robert J. Kleberg, Jr. and Helen C. Kleberg Foundation (NA)
  • Division of Intramural Research (NA)
  • Fairbairn Family Foundation (NA)
  • Bay Area Lyme Foundation (NA)
  • National Science Foundation (DGE-1147470)
  • HHS | National Institutes of Health (5T32AI007290)
  • HHS | National Institutes of Health (F32 AI124558-01)
  • Stanford University (NA)

This publication has 41 references indexed in Scilit: